On January 13, an open-label phase-I/II study on a therapeutic approach in advanced cervical cancer was initiated at the CRC Hannover. The principal investigator is Prof. Peter Hillemanns, cervical cancer expert at the Hannover Medical School and S3 guideline coordinator. The aims of this study are to investigate the effects of an additional therapeutic vaccination against HPV-16 on the body’s own defense system and to determine the vaccine’s safety and adverse event profiles. Study patients will receive their standard chemotherapy in the Department of Gynecology and Obstetrics of the Hannover Medical School. The additional experimental treatment that is part of this study will be performed by the early-phase clinical drug research team of the Hannover Medical School at the CRC Hannover. Patients participating in this trial benefit from highly qualified interdisciplinary care in an early-phase clinical trial and from the research-oriented equipment and the broad spectrum of diagnostic and imaging methods available at the CRC Hannover, providing optimal support in quantifying the success of the therapy.